Gene Target Group OMD+ — Enhancing Testing Efficiency and Reducing Labor

Gene Target Group focuses on gene technology and testing platform development, specializing in applying biochip technology for cancer prevention and control, chronic disease screening, rapid infectious disease detection, and various veterinary disease analyses.

Last year, supported by the Ministry of Economic Affairs’ Industrial Development Bureau through the Industry Upgrade Innovation Platform (TIIP), the company successfully developed the One-Station Molecular Decoder+ (OMD+) — a one-stop molecular chip operating system. This AI-powered automated biochip detection system replaces traditional gene analysis techniques, enabling operation without specialized personnel. It effectively saves labor, reduces labor costs, minimizes human error, and meets the demand for processing multiple samples simultaneously, thereby significantly cutting testing time and costs while greatly improving efficiency.

Challenges of Traditional Testing

Traditional testing relies heavily on manual operations, performing one test per sample, making the process cumbersome and time-consuming. The large volume of samples and data entry increases the likelihood of errors and low efficiency.

The one-stop molecular chip operating system designed by Gene Target Group addresses these issues through full automation, solving manpower shortages, poor test quality, and inaccuracies caused by manual interpretation. It can process over 32 samples simultaneously (compared to one at a time with conventional equipment), completing the entire testing workflow—from sample submission to report generation—in under three hours.

Breakthrough in Cancer Detection

Encouraged by the support from the innovation program, Gene Target Group also developed a cancer detection biochip capable of tracking the entire prevention-to-treatment process.

Gene Target Group highlights the growing clinical demand for gene testing, which now extends beyond rapid infectious disease diagnostics to include cancer diagnosis and risk analysis for major disease prevention.

In most molecular biology labs in Taiwan, over 70% of testing time is spent on manual sample preprocessing (such as receiving, centrifuging, uncapping, sorting, reagent addition), detection, result interpretation, and archiving, which significantly delays turnaround time. Heavy manual handling also raises biosafety risks for lab personnel.

Automated System Benefits

With Gene Target Group’s automated biochip detection system, operators only need to load samples and reagents. All procedures—including extraction, purification, amplification, calibration, reaction, and interpretation—are fully automated. This reduces technical barriers, minimizes human error, lowers labor, time, and reagent costs, and reduces infection risks by limiting sample contact.

Additionally, by marketing both the equipment and biochip reagents, Gene Target Group can overcome the regional limitations typical of traditional gene testing companies and expand sales globally, enhancing its commercial value.